

Fibroblast Growth Factor 21 Prevents Atherosclerosis by Regulatory Element-Binding Protein-2 and Induction of

Circulation

131, 1861-1871

DOI: [10.1161/circulationaha.115.015308](https://doi.org/10.1161/circulationaha.115.015308)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 72.	6.8	62
2	Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice. Cardiovascular Diabetology, 2015, 14, 77.	6.8	19
3	Vascular protection with fibroblast growth factor 21 in diabetes: Its potential beyond glucose and lipid control. International Journal of Cardiology, 2015, 199, 403-404.	1.7	2
4	Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1029-H1038.	3.2	78
5	Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Molecular Endocrinology, 2015, 29, 1400-1413.	3.7	106
6	Dietary Niacin Supplementation Suppressed Hepatic Lipid Accumulation in Rabbits. Asian-Australasian Journal of Animal Sciences, 2016, 29, 1748-1755.	2.4	15
7	Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases. Journal of Diabetes Research, 2016, 2016, 1-8.	2.3	37
8	Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. Diabetes and Metabolism Journal, 2016, 40, 22.	4.7	42
9	Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism. Lipids in Health and Disease, 2016, 15, 109.	3.0	19
10	FGF21 represses cerebrovascular aging via improving mitochondrial biogenesis and inhibiting p53 signaling pathway in an AMPK-dependent manner. Experimental Cell Research, 2016, 346, 147-156.	2.6	43
11	FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats. Scientific Reports, 2016, 6, 29582.	3.3	30
12	Single ingestion of soy β -conglycinin induces increased postprandial circulating FGF21 levels exerting beneficial health effects. Scientific Reports, 2016, 6, 28183.	3.3	42
13	Shedding light on FGF21: A potential negative regulator of PCSK9. International Journal of Cardiology, 2016, 214, 75-76.	1.7	8
14	Targeting endoplasmic reticulum stress in liver disease. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1041-1052.	3.0	34
15	Comprehensive Metabolomic Characterization of Coronary Artery Diseases. Journal of the American College of Cardiology, 2016, 68, 1281-1293.	2.8	186
16	Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4886-4894.	3.6	41
17	A Fibroblast Growth Factor 21-Dependent Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. Molecular Pharmacology, 2016, 90, 437-446.	2.3	22
18	The progress and challenges in metabolic research in China. IUBMB Life, 2016, 68, 847-853.	3.4	7

#	ARTICLE	IF	CITATIONS
19	Hyperlipidemia and hepatitis in liver-specific CREB3L3 knockout mice generated using a one-step CRISPR/Cas9 system. Scientific Reports, 2016, 6, 27857.	3.3	31
20	Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions. Lipids in Health and Disease, 2016, 15, 208.	3.0	9
21	Serum concentrations of fibroblast growth factor 21 are elevated in patients with congenital or acquired lipodystrophy. Cytokine, 2016, 83, 239-244.	3.2	18
22	Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives. Pharmacological Reports, 2016, 68, 837-846.	3.3	43
23	The FGF21-â€œadiponectin axis in controlling energy and vascular homeostasis. Journal of Molecular Cell Biology, 2016, 8, 110-119.	3.3	68
24	Overexpression of β -Klotho in Adipose Tissue Sensitizes Male Mice to Endogenous FGF21 and Provides Protection From Diet-Induced Obesity. Endocrinology, 2016, 157, 1467-1480.	2.8	55
25	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Expert Review of Gastroenterology and Hepatology, 2016, 10, 393-403.	3.0	25
26	Practical prospects for boosting hepatic production of the â€œpro-longevityâ€•hormone FGF21. Hormone Molecular Biology and Clinical Investigation, 2017, 30, .	0.7	4
27	The moderate essential amino acid restriction entailed by low-protein vegan diets may promote vascular health by stimulating FGF21 secretion. Hormone Molecular Biology and Clinical Investigation, 2017, 30, .	0.7	10
28	Fibroblast growth factor 21 â€œ a key player in cardiovascular disorders?. Hormone Molecular Biology and Clinical Investigation, 2017, 30, .	0.7	4
29	Mouse models of atherosclerosis: a historical perspective and recent advances. Lipids in Health and Disease, 2017, 16, 12.	3.0	130
30	Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2017, 6, .	3.7	29
31	Haematopoietic TLR4 deletion attenuates perivascular brown adipose tissue inflammation in atherosclerotic mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 946-957.	2.4	12
32	FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in mice. Clinical Science, 2017, 131, 1877-1893.	4.3	38
33	The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension. Current Hypertension Reports, 2017, 19, 28.	3.5	52
34	The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis, 2017, 257, 259-265.	0.8	54
35	Fibroblast growth factor 21 attenuates calcification of vascular smooth muscle cells in vitro. Journal of Pharmacy and Pharmacology, 2017, 69, 1802-1816.	2.4	26
36	Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity. Cellular Signalling, 2017, 40, 10-21.	3.6	72

#	ARTICLE	IF	CITATIONS
37	The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity. <i>Cell Metabolism</i> , 2017, 26, 493-508.e4.	16.2	113
38	Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. <i>Cytokine and Growth Factor Reviews</i> , 2017, 38, 59-65.	7.2	41
39	Associations of fibroblast growth factor 21 with cardiovascular risk and β^2 -cell function in patients who had no history of diabetes. <i>Clinica Chimica Acta</i> , 2017, 472, 80-85.	1.1	5
40	Fibroblast Growth Factor 21â€™Metabolic Role in Mice and Men. <i>Endocrine Reviews</i> , 2017, 38, 468-488.	20.1	192
41	Fibroblast growth factor 21 plays an inhibitory role in vascular calcification inÂvitro through OPG/RANKL system. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 578-586.	2.1	19
42	Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK/BMP/Smad pathway. <i>International Journal of Molecular Medicine</i> , 2017, 41, 51-60.	4.0	26
43	Citreoviridin induces triglyceride accumulation in hepatocytes through inhibiting PPAR- β inÂvivo and inÂvitro. <i>Chemico-Biological Interactions</i> , 2017, 273, 212-218.	4.0	6
44	FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPAR β and PPAR γ Agonists. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 834-845.	2.8	44
45	Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. <i>Ageing Research Reviews</i> , 2017, 35, 200-221.	10.9	483
46	Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis. <i>Endocrinology and Metabolism</i> , 2017, 32, 145.	3.0	8
47	Adrenergic receptor-mediated activation of FGF-21-adiponectin axis exerts atheroprotective effects in brown adipose tissue-transplanted apoE mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1097-1103.	2.1	11
48	FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1â€™7) Axis in Mice. <i>Cell Metabolism</i> , 2018, 27, 1323-1337.e5.	16.2	104
49	Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance. <i>Journal of Nutritional Biochemistry</i> , 2018, 57, 189-196.	4.2	31
50	Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. <i>Cell Death and Disease</i> , 2018, 9, 227.	6.3	85
51	Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 83, 11-17.	3.4	51
52	Pharmacokinetics, tissue distribution, and excretion of FGFâ€™21 following subcutaneous administration in rats. <i>Drug Testing and Analysis</i> , 2018, 10, 1061-1069.	2.6	5
53	The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2018, 269, 86-91.	0.8	9
54	Conditioned medium from contracting skeletal muscle cells reverses insulin resistance and dysfunction of endothelial cells. <i>Metabolism: Clinical and Experimental</i> , 2018, 82, 36-46.	3.4	14

#	ARTICLE	IF	CITATIONS
56	FGF21 induced by carbon monoxide mediates metabolic homeostasis via the PERK/ATF4 pathway. <i>FASEB Journal</i> , 2018, 32, 2630-2643.	0.5	39
57	The role of suppression of hepatic SCD1 expression in the metabolic effects of dietary methionine restriction. <i>Applied Physiology, Nutrition and Metabolism</i> , 2018, 43, 123-130.	1.9	6
58	Fibroblast growth factors 19 and 21 in acute liver damage. <i>Annals of Translational Medicine</i> , 2018, 6, 257-257.	1.7	11
59	Acid fibroblast growth factor facilitates the progression of atherosclerotic plaques regardless of alterations in serum lipid expression levels in HFD-fed ApoE ^{-/-} mice. <i>Molecular Medicine Reports</i> , 2018, 18, 1025-1030.	2.4	3
60	Cholesterol Efflux: Does It Contribute to Aortic Stiffening?. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 23.	1.6	8
61	Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice. <i>Stroke</i> , 2018, 49, 3039-3049.	2.0	36
62	Adiposity Is a Key Correlate of Circulating Fibroblast Growth Factor-21 Levels in African Males with or without Type 2 Diabetes Mellitus. <i>Journal of Obesity</i> , 2018, 2018, 1-8.	2.7	9
63	Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1825-1834.	5.6	35
64	Fibroblast growth factor 21 inhibits atherosclerosis in apoE ^{-/-} mice by ameliorating Fas-mediated apoptosis. <i>Lipids in Health and Disease</i> , 2018, 17, 203.	3.0	23
65	The role of FGF21 in type 1 diabetes and its complications. <i>International Journal of Biological Sciences</i> , 2018, 14, 1000-1011.	6.4	23
66	CREBH Regulates Systemic Glucose and Lipid Metabolism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1396.	4.1	62
67	FGF Family: From Drug Development to Clinical Application. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1875.	4.1	110
68	A2A Receptor Activation Attenuates Hypertensive Cardiac Remodeling via Promoting Brown Adipose Tissue-Derived FGF21. <i>Cell Metabolism</i> , 2018, 28, 476-489.e5.	16.2	80
69	RPS3A positively regulates the mitochondrial function of human periaortic adipose tissue and is associated with coronary artery diseases. <i>Cell Discovery</i> , 2018, 4, 52.	6.7	21
70	Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 821-828.	2.0	10
71	Endothelial cell senescence in aging-related vascular dysfunction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1802-1809.	3.8	232
72	Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer. <i>Cancers</i> , 2019, 11, 1154.	3.7	23
73	The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. , 2019, 203, 107401.		86

#	ARTICLE	IF	CITATIONS
74	Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. <i>Clinica Chimica Acta</i> , 2019, 498, 30-37.	1.1	28
75	Lyophilized Maqui (<i>Aristotelia chilensis</i>) Berry Induces Browning in the Subcutaneous White Adipose Tissue and Ameliorates the Insulin Resistance in High Fat Diet-Induced Obese Mice. <i>Antioxidants</i> , 2019, 8, 360.	5.1	28
76	Inhibition of vascular neointima hyperplasia by FGF21 associated with FGFR1/Syk/NLRP3 inflammasome pathway in diabetic mice. <i>Atherosclerosis</i> , 2019, 289, 132-142.	0.8	36
77	The FGF metabolic axis. <i>Frontiers of Medicine</i> , 2019, 13, 511-530.	3.4	97
78	Fibroblast growth factor 21 Ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPK α signaling pathway. <i>Cell Death and Disease</i> , 2019, 10, 665.	6.3	37
79	Effects of granulocyte colony-stimulating factor on rabbit carotid and porcine heart models of chronic obliterative arterial disease. <i>Molecular Medicine Reports</i> , 2019, 19, 4569-4578.	2.4	0
80	Therapeutic effect of dichloroacetate against atherosclerosis via hepatic FGF21 induction mediated by acute AMPK activation. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-12.	7.7	13
81	Adiponectin improves diabetic nephropathy by inhibiting necrotic apoptosis. <i>Archives of Medical Science</i> , 2019, 15, 1321-1328.	0.9	21
82	Fibroblast Growth Factor 21 Attenuates Vascular Calcification by Alleviating Endoplasmic Reticulum Stress Mediated Apoptosis in Rats. <i>International Journal of Biological Sciences</i> , 2019, 15, 138-147.	6.4	36
83	Mutual promotion of FGF21 and PPAR γ attenuates hypoxia-induced pulmonary hypertension. <i>Experimental Biology and Medicine</i> , 2019, 244, 252-261.	2.4	18
84	Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and cardiovascular events: Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2019, 287, 46-53.	0.8	17
85	Fibroblast growth factor 21 ameliorates pancreatic fibrogenesis via regulating polarization of macrophages. <i>Experimental Cell Research</i> , 2019, 382, 111457.	2.6	22
86	A review of fibroblast growth factor 21 in diabetic cardiomyopathy. <i>Heart Failure Reviews</i> , 2019, 24, 1005-1017.	3.9	26
87	Monocyte chemoattractant protein-1 (MCP-1) and fibroblast growth factor-21 (FGF-21) as biomarkers of subclinical atherosclerosis in women. <i>Experimental Gerontology</i> , 2019, 124, 110624.	2.8	24
88	Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1275-1287.	2.4	36
89	Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. <i>Cell Reports</i> , 2019, 26, 2738-2752.e4.	6.4	115
90	FGF21 Protects Against Hypoxia Injury Through Inducing HSP72 in Cerebral Microvascular Endothelial Cells. <i>Frontiers in Pharmacology</i> , 2019, 10, 101.	3.5	22
91	Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. <i>Toxicology and Applied Pharmacology</i> , 2019, 370, 170-177.	2.8	18

#	ARTICLE	IF	CITATIONS
92	The roles of FGF21 in atherosclerosis pathogenesis. Reviews in Endocrine and Metabolic Disorders, 2019, 20, 103-114.	5.7	27
93	Emerging Structureâ€“Function Paradigm of Endocrine FGFs in Metabolic Diseases. Trends in Pharmacological Sciences, 2019, 40, 142-153.	8.7	24
94	Fibroblast growth factor 21 in chronic kidney disease. Journal of Nephrology, 2019, 32, 365-377.	2.0	38
95	Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signalingâ€“dependent manner. Journal of Cellular and Molecular Medicine, 2019, 23, 1059-1071.	3.6	39
96	Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 882-888.	3.6	16
97	Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. Journal of Diabetes Investigation, 2019, 10, 1059-1067.	2.4	40
98	Fibroblast growth factor 21 in chronic kidney disease. Clinica Chimica Acta, 2019, 489, 196-202.	1.1	29
99	Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases. International Journal of Peptide Research and Therapeutics, 2020, 26, 107-119.	1.9	8
100	Organokines in disease. Advances in Clinical Chemistry, 2020, 94, 261-321.	3.7	24
101	Adipokines and Inflammation: Focus on Cardiovascular Diseases. International Journal of Molecular Sciences, 2020, 21, 7711.	4.1	48
103	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism, 2020, 42, 101092.	6.5	197
104	Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy. Lipids in Health and Disease, 2020, 19, 241.	3.0	27
105	The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nature Reviews Endocrinology, 2020, 16, 654-667.	9.6	280
106	Structures and anti-atherosclerotic effects of 1,6-Î±-glucans from Fructus Corni. International Journal of Biological Macromolecules, 2020, 161, 1346-1357.	7.5	17
108	FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages. Journal of Neuroinflammation, 2020, 17, 257.	7.2	97
109	Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model. International Journal of Molecular Sciences, 2020, 21, 6836.	4.1	11
110	FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Frontiers in Endocrinology, 2020, 11, 601290.	3.5	111
111	Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. Journal of the American Heart Association, 2020, 9, e015226.	3.7	34

#	ARTICLE	IF	CITATIONS
112	Pulse Wave Velocity Is Associated with Increased Plasma oxLDL in Ageing but Not with FGF21 and Habitual Exercise. <i>Antioxidants</i> , 2020, 9, 221.	5.1	3
113	Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoE ^{-/-} Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 223.	3.5	129
114	Effects of exercise training and detraining on atheromatous matrix metalloproteinase activity in mice. <i>Atherosclerosis</i> , 2020, 299, 15-23.	0.8	3
115	A novel selective PPAR α modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. <i>PLoS ONE</i> , 2020, 15, e0235362.	2.5	12
116	Adenosine A2A receptor activation prevents DOCA-salt induced hypertensive cardiac remodeling via iBAT. <i>Biochemical and Biophysical Research Communications</i> , 2020, 525, 224-230.	2.1	5
117	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 679-704.	4.5	121
118	Growth factor regulatory system: a new system for not truly recognized organisms. <i>Science China Life Sciences</i> , 2020, 63, 443-446.	4.9	2
119	Serum fibroblast growth factor 21 level is increased in pre-eclampsia patients: Association with blood pressure and lipid profile. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 375-381.	1.3	6
120	Enterohepatic Transcription Factor CREB3L3 Protects Atherosclerosis via SREBP Competitive Inhibition. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 949-971.	4.5	11
121	Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects. <i>Genes</i> , 2021, 12, 307.	2.4	8
122	Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice. <i>Stem Cell Research and Therapy</i> , 2021, 12, 133.	5.5	14
123	Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model. <i>Endocrinology and Metabolism</i> , 2021, 36, 157-170.	3.0	11
124	Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2021, 36, 57-59.	3.0	1
125	FGF21 promotes ischaemic angiogenesis and endothelial progenitor cells function under diabetic conditions in an AMPK/NAD ⁺ -dependent manner. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3091-3102.	3.6	21
126	Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. <i>Cardiovascular Research</i> , 2022, 118, 489-502.	3.8	34
127	Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002126.	2.8	5
128	Roles of Fibroblast Growth Factors and Their Therapeutic Potential in Treatment of Ischemic Stroke. <i>Frontiers in Pharmacology</i> , 2021, 12, 671131.	3.5	29
129	Myeloid-derived growth factor inhibits inflammation and alleviates endothelial injury and atherosclerosis in mice. <i>Science Advances</i> , 2021, 7, .	10.3	33

#	ARTICLE	IF	CITATIONS
130	FGF21 and Chronic Kidney Disease. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154738.	3.4	15
131	The potential role of plasma fibroblast growth factor 21 as a diagnostic biomarker for abdominal aortic aneurysm presence and development. <i>Life Sciences</i> , 2021, 274, 119346.	4.3	6
132	Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1091-1109.	5.7	14
133	Peptidoglycan Recognition Protein 1 Attenuates Atherosclerosis by Suppressing Endothelial Cell Adhesion. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 615-621.	1.9	4
134	BMP4-mediated browning of perivascular adipose tissue governs an anti-inflammatory program and prevents atherosclerosis. <i>Redox Biology</i> , 2021, 43, 101979.	9.0	18
135	The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms. <i>Frontiers in Endocrinology</i> , 2021, 12, 598008.	3.5	5
136	Elabela prevents angiotensin II-induced apoptosis and inflammation in rat aortic adventitial fibroblasts via the activation of FGF21-ACE2 signaling. <i>Journal of Molecular Histology</i> , 2021, 52, 905-918.	2.2	10
137	Estrogen-Wnt signaling cascade regulates expression of hepatic fibroblast growth factor 21. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E292-E304.	3.5	11
138	High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 705273.	2.4	12
139	CREBH Systemically Regulates Lipid Metabolism by Modulating and Integrating Cellular Functions. <i>Nutrients</i> , 2021, 13, 3204.	4.1	2
140	FGF21 ameliorates hepatic fibrosis by multiple mechanisms. <i>Molecular Biology Reports</i> , 2021, 48, 7153-7163.	2.3	10
141	CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	12
142	Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance. <i>Journal of Animal Science and Biotechnology</i> , 2021, 12, 97.	5.3	9
143	Association of Coronary Artery Disease and Metabolic Syndrome: Usefulness of Serum Metabolomics Approach. <i>Frontiers in Endocrinology</i> , 2021, 12, 692893.	3.5	8
144	Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1276, 137-156.	1.6	18
145	Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells. <i>Auris Nasus Larynx</i> , 2020, 47, 870-880.	1.2	9
146	FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis. <i>Experimental Cell Research</i> , 2020, 393, 112108.	2.6	59
147	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. <i>Clinical Science</i> , 2020, 134, 1775-1799.	4.3	25

#	ARTICLE	IF	CITATIONS
148	Current understanding and controversies on the clinical implications of fibroblast growth factor 21. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 311-328.	6.1	7
149	Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. PLoS ONE, 2015, 10, e0133496.	2.5	84
150	Metabolic remodeling induced by mitokines in heart failure. Aging, 2019, 11, 7307-7327.	3.1	9
151	Adipose tissue-derived omentin-1 attenuates arterial calcification via AMPK/Akt signaling pathway. Aging, 2019, 11, 8760-8776.	3.1	17
152	Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease. Frontiers in Physiology, 2021, 12, 764503.	2.8	5
153	SERUM LEVEL OF FIBROBLAST GROWTH FACTOR 21 AND INSULIN RESISTANCE SYNDROME IN PATIENTS WITH CORONARY ARTERY DISEASE WITH OBESITY. Bulletin of Problems Biology and Medicine, 2018, 1, 108.	0.1	0
154	Metabolic Values of Fibroblasts Growth Factor 21 in Patients with Coronary Artery Disease and Obesity. Ukraïns'kij Åurnál Medicini BÅologÅ-Ta Sportu, 2018, 3, 110-114.	0.2	0
157	Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. Frontiers in Cardiovascular Medicine, 2021, 8, 764038.	2.4	37
158	Adiponectin receptor agonist AdipoRon blocks skin inflammågeing by regulating mitochondrial dynamics. Cell Proliferation, 2021, 54, e13155.	5.3	16
159	NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. , 2020, , 169-197.		0
160	Fibroblast growth factor 21 delayed endothelial replicative senescence and protected cells from HO-induced premature senescence through SIRT1. American Journal of Translational Research (discontinued), 2017, 9, 4492-4501.	0.0	28
161	FGF21 inhibitor suppresses the proliferation and migration of human umbilical vein endothelial cells through the eNOS/PI3K/AKT pathway. American Journal of Translational Research (discontinued), 2017, 9, 5299-5307.	0.0	6
162	A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction. American Journal of Translational Research (discontinued), 2018, 10, 2958-2966.	0.0	9
163	Fibroblast growth factor 21 attenuates inflammation and oxidative stress in atherosclerotic rat via enhancing the Nrf1-ARE signaling pathway. International Journal of Clinical and Experimental Pathology, 2018, 11, 1308-1317.	0.5	11
164	Ethyl acetate extract of sappanwood alleviates experimental atherosclerosis in rats through changes in FGF21 and SREBP-2 expression. International Journal of Clinical and Experimental Pathology, 2020, 13, 220-229.	0.5	2
165	The impact of different adipose depots on cardiovascular disease. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	5
166	Fibroblast growth factor 21 attenuates salt-sensitive hypertension-induced nephropathy through anti-inflammation and anti-oxidation mechanism. Molecular Medicine, 2021, 27, 147.	4.4	8
167	Effects of an interdisciplinary weight loss program on fibroblast growth factor 21 and inflammatory biomarkers in women with overweight and obesity. Archives of Endocrinology and Metabolism, 2021, 65, .	0.6	2

#	ARTICLE	IF	CITATIONS
168	Dietary protein and amino acid restriction: Roles in metabolic health and aging-related diseases. <i>Free Radical Biology and Medicine</i> , 2022, 178, 226-242.	2.9	19
169	Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia. <i>Cells</i> , 2022, 11, 313.	4.1	12
170	FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPAR γ . <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1034-1049.	3.6	7
171	Serum Fibroblast Growth Factor 21 Level Is Associated with Aortic Stiffness in Patients on Maintenance Hemodialysis. <i>International Journal of Hypertension</i> , 2022, 2022, 1-8.	1.3	2
172	Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication. <i>Metabolites</i> , 2022, 12, 237.	2.9	2
173	Fibroblast growth factor 21 reverses high-fat diet-induced impairment of vascular function via the anti-oxidative pathway in ApoE knockout mice. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2451-2461.	3.6	9
174	Serum FGF21 Levels Predict the MACE in Patients With Myocardial Infarction After Coronary Artery Bypass Graft Surgery. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 850517.	2.4	2
175	Mitochondrial uncoupling protein 1 antagonizes atherosclerosis by blocking NLRP3 inflammasome-dependent interleukin-1 β production. <i>Science Advances</i> , 2021, 7, eabl4024.	10.3	27
176	The role of FGF21 in the pathogenesis of cardiovascular disease. <i>Chinese Medical Journal</i> , 2021, 134, 2931-2943.	2.3	25
179	The Effect of All Extremity High Intensity Interval Training on Athero-Protective Factors and Endothelial Function in Overweight and Obese Women.. <i>International Journal of Preventive Medicine</i> , 2021, 12, 141.	0.4	2
180	Adipokines, adiposity, and atherosclerosis. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 272.	5.4	38
181	The Association Between FGF21 and Diabetic Erectile Dysfunction: Evidence from Clinical and Animal Studies. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	0
182	Circulating Fibroblast Growth Factor 21 and Total Testosterone in Type 2 Diabetes Mellitus Men With Coronary Heart Disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	2
183	Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPAR γ /FGF21 Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 1003-1023.	4.5	8
184	Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 359-382.	9.4	16
186	Fibroblast growth factor 21 is associated with widening QRS complex and prolonged corrected QT interval in patients with stable angina. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	1.7	0
187	FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity. <i>Circulation</i> , 2022, 146, 1537-1557.	1.6	55
188	Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. <i>International Journal of Biological Sciences</i> , 2023, 19, 66-88.	6.4	11

#	ARTICLE	IF	CITATIONS
189	Glucose and lipopolysaccharide differentially regulate fibroblast growth factor 21 in healthy male human volunteers – A prospective crossover trial. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5998-6005.	3.6	1
190	Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects. <i>Nature Communications</i> , 2022, 13, .	12.8	5
192	Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
194	Liver-derived <scp>FGF21</scp> is required for the effect of time-restricted feeding on high-fat diet-induced fatty liver in mice. <i>FASEB Journal</i> , 2023, 37, .	0.5	4
195	The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
196	Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis. <i>Hepatology</i> , 2023, 78, 1506-1524.	7.3	6
197	IntiCom-DB: A Manually Curated Database of Inter-Tissue Communication Molecules and Their Communication Routes. <i>Biology</i> , 2023, 12, 833.	2.8	0
198	The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	10
199	Toxicokinetics of recombinant human fibroblast growth factor 21 for injection in cynomolgus monkey for 3 months. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
200	Myeloid-derived growth factor alleviates non-alcoholic fatty liver disease alleviates in a manner involving IKK β /NF- κ B signaling. <i>Cell Death and Disease</i> , 2023, 14, .	6.3	7
201	Grape polyphenols may prevent high fat diet-induced dampening of the hypothalamic-pituitary-adrenal axis in male mice. <i>Journal of the Endocrine Society</i> , 0, , .	0.2	0
202	Fibroblast growth factor 21 in metabolic syndrome. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	3
203	Batokine in Central Nervous System Diseases. <i>Molecular Neurobiology</i> , 0, , .	4.0	0
204	New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk. <i>Nutrients</i> , 2023, 15, 3970.	4.1	4
205	New Dawn for Atherosclerosis: Vascular Endothelial Cell Senescence and Death. <i>International Journal of Molecular Sciences</i> , 2023, 24, 15160.	4.1	5
206	Intermittent fasting favorably modulates adipokines and potentially attenuates atherosclerosis. <i>Biochemical Pharmacology</i> , 2023, 218, 115876.	4.4	3
207	Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis. <i>Archives of Endocrinology and Metabolism</i> , 2023, 68, .	0.6	1
208	Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes. <i>BMC Endocrine Disorders</i> , 2023, 23, .	2.2	0

#	ARTICLE	IF	CITATIONS
209	Altered Red Blood Cell Fatty Acid and Serum Adipokine Profiles in Subjects with Obesity. Biomedicines, 2023, 11, 3320.	3.2	0
210	Endocrinology and metabolism. , 2024, , 179-295.		0
211	Growth factors reviews. , 2024, , 19-112.		0
212	Adipose c-Jun NH2-terminal kinase promotes angiotensin II-induced and deoxycorticosterone acetate salt-induced hypertension and vascular dysfunction by inhibition of adiponectin production and activation of SGK1 in mice. Journal of Hypertension, 2024, 42, 856-872.	0.5	0
213	SREBPs as the potential target for solving the polypharmacy dilemma. Frontiers in Physiology, 0, 14, .	2.8	0
214	The FGF metabolic axis. , 2024, , 1-18.		0
215	Exerkines and cardiometabolic benefits of exercise: from bench to clinic. EMBO Molecular Medicine, 2024, 16, 432-444.	6.9	0
216	Current status and future perspectives of FGF21 analogues in clinical trials. Trends in Endocrinology and Metabolism, 2024, , .	7.1	0
217	Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease. Medical Review, 2024, 4, 158-168.	1.2	0